International Journal of Science and Research (IJSR)
ISSN: 2319-7064
SJIF (2022): 7.942

A Systematic Review of Peak Expiratory Flow Rate (PEFR) Values in Pre and Post Nebulization with Two Different Techniques in Adult Asthmatic Patients

Sreekanth Komath Mohan[1], Shashidhar Kotian M[2], Udayakumar Rao[3], Namitha R[4], Suhair PP[5], Hasib Ali[6]

[1]Research Scholar, Srinivas University, Mukka, South Karnataka

[2] Professor in Research, Srinivas University, Mukka, South Karnataka

[3]Dean - College of Applied Medical Sciences, Srinivas University, Mukka, South Karnataka

[4]Consultant at Iqraa Hospital & Research Centre, Calicut, Kerala.

[5]Respiratory Therapist at Iqraa Hospital & Research Centre, Calicut, Kerala

Abstract: ***Peak Expiratory Flow Rate (PEFR) is the primary outcome metric in this review of the relative efficacy of masks and mouthpiece nebulization in the treatment of asthma. Following a comprehensive search of numerous databases, which include Scopus, CINAHL, PubMed, EMBASE, and the Cochrane Central Register of Controlled Studies (CENTRAL), eight randomised managed studies were observed that fulfilled the inclusion standards. The research that had been chosen had been published during the past 5 years and covered a huge variety of those who had asthma, whether it became mild persistent bronchial asthma, uncontrolled allergies, or extreme exacerbations. The suggested PEFR improvement after mouthpiece nebulization changed from 18% to 31%, with the majority of studies locating enhancements of 20–30%. In contrast, mask nebulization revealed a relatively decreased mean percentage PEFR upgrade of 12–21%. Inspiring troubles approximately the viable advantages of mouthpiece nebulization versus mask processes were raised through the observed discrepancies. Study variability is due in part to the fact that researchers checked out variables impacting response, inclusive of the severity of asthma, the sort of medication used, the duration of remedy, the degree to which respondents adhered to the approach, their baseline lung function, and the presence of any co-morbidities. The Cochrane Risk of Bias evaluation verified the need for rigorous methods for future studies. Significant therapeutic implications for acute asthma exacerbations and regular care come from the consequences, which show that mouthpiece nebulizers may offer truly large PEFR enhancements. For those who are sensitive to masks, mouthpiece nebulization continues to be an option to remember. Scores for asthma manipulation, quality of life, adverse results, and healthcare use are other consequences that must be the point of interest of the destiny examination in addition to PEFR. Larger meta-analyses are necessary to corroborate those early consequences and provide useful evidence-based decision-making in adult asthma management.***

Keywords: Peak Expiratory Flow Rate (PEFR), Mask Nebulization and Mouthpiece Nebulization

1. Introduction

1.1 Peak Expiratory Flow Rate (PEFR) and its Role in Asthma Management

Peak Expiratory Flow Rate (PEFR), also known as peak flow, represents the greatest rate of airflow created all through a robust exhale from a full lung inflate [1]. It offers a trustworthy, non-invasive, and, without difficulty, an easily assessable measure of airway obstruction severity in persons with asthma [2] Low PEFR readings suggest constricted airways due to bronchospasm or inflammation, a standard sign of bronchial asthma exacerbations [3]. Monitoring PEFR modifications allows asthma control, perception of worsening, and guidance of treatment suggestions. Regularly charting PEFR ranges allows patients and healthcare practitioners to: Identify factors worrying about their bronchial asthma and regulate their remedy appropriately [4].Assess the efficacy of medication and adjust regimens as appropriate [5].Make educated choices about getting medical help at some stage in asthma attacks (American Academy of Allergy, Asthma [6].

1.2 Nebulization Techniques in Asthma Management: Balancing Advantages and Disadvantages

Nebulization, a cornerstone of asthma remedies, distributes the remedy at once into the airways as a mist, giving on-the-spot remedies for acute signs. However, deciding on the proper approach includes thinking about many advantages and drawbacks [7],[11]:

1.2.1 Mask Nebulization: Advantages: Covers each nostril and mouth for powerful drug management, best for all ages, particularly small children or people with coordination challenges [8],[12].Disadvantages: bulky and time-consuming (20–30 minutes); risk of face discomfort or claustrophobia; threat of contamination if no longer cleaned successfully.

1.2.2 Mouthpiece Nebulization: Advantages: compact and portable; faster treatment length (10–15 min); lowers the risk of face pain. Disadvantages: It requires robust coordination and a breath-retaining method, which might not be ideal for youngsters or people with cognitive impairments [9],[13].

1.2.3 Mesh Nebulizers: Advantages: portable, quiet operation; faster treatment length (5–10 minutes); less medicinal drug waste. Disadvantages: higher initial value; less resilient than normal nebulizers; wishes battery or energy source [10].

1.3 Navigating the Trade-Offs

The best nebulization process varies depending on individual necessities and tastes. For younger infants or people with low coordination, a mask is normally perfect. In comparison, people with strong skills might also decide upon the mobility and quicker administration of a mouthpiece nebulizer.[14],[19] Mesh nebulizers offer ease and speed, but they come at a price. [15],[16]Ultimately, healthcare providers ought to assist patients in selecting the most suitable approach depending on parameters that to include age, coordination, treatment frequency, and medicinal drug type.

1.4 Comparing PEFR Changes in Mask vs. Mouthpiece Nebulization for Adult Asthma Management

Peak Expiratory Flow Rate (PEFR), an incredible tool for evaluating airway obstruction, plays a vital role in controlling adult bronchial asthma [17],[26] while nebulized bronchodilators supply fast relief throughout exacerbations, the management mechanism greatly determines their efficacy. Comparing PEFR modifications following mask and mouthpiece nebulization bears incredible value for numerous reasons:

Optimising Patient Responses: Different approaches indicate numerous pharmaceutical deposition styles inside the airways [18],[27]. While masks, usually used for youngsters, could no longer ensure adequate delivery in adults, mouthpiece nebulizers demand greater coordination, which would possibly allow more focused deposition. Comparing PEFR enhancements shows which technique ends in better bronchodilation for individual patients, permitting individualised therapy options for more effective symptom management and decreasing exacerbation risk [19],[28].Guiding Clinical Decisions: Healthcare practitioners depend upon objective records for manual asthma therapy. Understanding the contrasting outcomes of masks and mouthpiece nebulization on PEFR allows them to adapt remedy programmes based totally on individual necessities and responses. A patient often showing greater PEFR development with a mouthpiece nebulizer would possibly gain from favouring this approach during acute stages. This information-driven approach fosters precision medicinal drugs, permitting both patients and healthcare professionals to treat asthma more effectively [20],[29].

Informing Technology Advancements: Nebulization technology is constantly developing, with mesh nebulizers permitting mobility and faster remedy periods. However, their effectiveness in comparison to conventional nebulizers, especially in terms of PEFR changes, stays under question. Rigorous comparisons among procedures, consisting of their affect on PEFR, may additionally drive future improvement and use of nebulization technologies, ensuring choice management and higher outcomes for adult asthma sufferers [21].In the end, methodically evaluating PEFR changes following masks and mouthpiece nebulization in adults surpasses primary medical interest. It gives the ability to alternate adult allergy care via: [22]-[25]. Individualizing treatment regimens depending on patient responses. Informing medical decision-making is based totally on objective data. Driving advances in nebulization technology for optimum delivery and higher patient results.

2. Objectives of the study

2.1 To evaluate the importance of PEFR and examine nebulization techniques in asthma management
2.2 To investigate PEFR changes after nebulization
2.3 To analyse the characteristics of the included studies
2.4 To compare PEFR changes with mask nebulization
2.5 To compare PEFR changes with mouthpiece nebulization
2.6 To Address the Risk of Bias in Included Studies
2.7 To Discuss Potential Explanations for Differences in Effectiveness

Performing a successful literature review is the cornerstone of evidence-based disciplines, together with evidence-based medicinal drugs. In this review, we use the search technique adopted for the systematic review of PEFR values in adult asthmatic patients. Asthmatic sufferers undergo post-nebulization using masks and mouthpiece techniques [30]. We spread our nets broadly, embracing recognised sites like: PubMed (MEDLINE). EMBASE: Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, Scopus [31]. Keywords were methodically picked a combination of MeSH keywords and unfastened-text phrases, inclusive of versions for: Population: patients, bronchial asthma. Intervention: nebulization, mouthpieces, masks, and bronchodilators; Outcome: PEFR, symptom control; study design: randomised managed trial, clinical trial [32]. Inclusion/Exclusion Criteria were set: Inclusion: studies regarding persons with asthma, evaluating masks and mouthpiece nebulization, measuring PEFR changes, or symptom control, published in English with full text accessible [33]. Exclusion: case reports, commentaries, research on children, and those missing appropriate final results [34]. Date Range: research published all through the preceding 5 years, to catch the most up-to-date breakthroughs [35]. This search method acts as our manual, leading us across the huge global database of study information. By applying accuracy and meticulousness, we are seeking to find out the most useful information to deal with our significant issues regarding nebulization effectiveness and enable improved asthma care for adults [36]-[39].

2.1 Screening Eligible Studies: A Rigorous Process

The inquiry began with a radical search across several databases, generating 785 feasible papers on mask vs. mouthpiece nebulization in adult bronchial asthma therapy [40]. Armed with clear dreams and pre-defined inclusion and exclusion standards, we proceeded with a rigorous screening system [41]. Initial Screening: This preliminary step, methodically analysing titles and abstracts, cut down the field to 210 articles with presumably applicable records

[42]. Full-Text Review: In addition to diving, I went into the complete content of those 210 articles. Regrettably, 165 papers could not be included for one-of-a-kind motives: Study Design (n = 55): These studies did not employ randomised managed trials or different relevant scientific trial designs [43]. Group (n = 35): Their interest wandered from the intended adult asthma group [44]. Intervention (n = 25): The trials did not compare masks and mouthpiece nebulization approaches [45]. Outcomes (n = 20): They lacked information on PEFR changes or symptom management measures. The Final Harvest: After this tough screening, it is satisfied to provide 45 high quality papers of research that meet all the inclusion necessities. These trials may be tested to examine mask vs. mouthpiece nebulization as a grownup asthma remedy [46].



Figure 1: Flowchart for Record Selection

The purpose of this research is to observe the available information on the effectiveness of mouthpiece nebulization vs. mask nebulization as a remedy for asthma in adults. Every study has its own unique set of traits, which include the author's details, the date of publication, the type of study, the wide variety of respondents, the intervention details, and the end measures, which include changes in PEFR after nebulization and symptom control. Validated instruments, including the Cochrane Risk of Bias Evaulation [47], can be used to perform the risk of bias assessment. In order to attain the important information, a reference management programme, separate reviewers, and a standardised form may be used. [48]

3. Results

3.1 Features of Research Included in the Review



Figure 2: Featured studies overview (including every study's year, population size, methodology, interventional particulars, and authors)

3.2 PEFR Changes with Mask Nebulization

Table 1: Mouthpiece Nebulization's Impact on PEFR with Various Medications

Study	*Patients*	*Intervention*	*Mean % Change in PEFR*
[49]	Adults with acute asthma exacerbation (n=20)	Mouthpiece nebulizer with salbutamol	31
[50]	Children with acute asthma exacerbation (n=45)	Mouthpiece nebulizer with albuterol	28
[51]	Children with mild persistent asthma (n=70)	Mouthpiece nebulizer with salbutamol	26
[52]	Adults hospitalized with asthma (n=80)	Mouthpiece nebulizer with budesonide	24
[53]	Adults with uncontrolled asthma (n=100)	Mouthpiece nebulizer with beclomethasone	22
[54]	Adults with acute asthma exacerbation (n=150)	Mouthpiece nebulizer with levalbuterol	21
[55]	Adults hospitalized for asthma (n=180)	Mouthpiece nebulizer with budesonide	18

Research on the effectiveness of mouthpiece nebulization in improving asthmatic lung capabilities (PEFR) is included inside the table. Nebulizers with mouthpieces significantly improved PEFR by 18% to 31% in the majority of trials. The included studies treated both children and adults with a variety of medicines, including salbutamol, albuterol, budesonide, and beclomethasone. Regardless of age group or drug type, the data demonstrate that mouthpiece nebulization notably improves lung function for asthma patients. Patient demographic, remedy, and presentation severity are some of the variables that might have an effect on the degree of development. Nevertheless, while comparing mask nebulization processes to mouthpiece nebulization, the latter has consistently shown higher PEFR benefits.

3.3 Various Claimed Benefits, Variability across Studies, Probable Factors

While the current table reveals a number of favourable increases in lung function (PEFR) following mouth piece nebulization for asthma, starting from 18% to 31%, decoding these outcomes entails admitting full-size variability among trials [56].

Several reasons make contributions to this modification:Missing statistics: Two studies lack essential data on pre- and post-PEFR modifications, limiting direct comparisons with others. [57]

Diverse patient populations: The studies recruited adults and childrens with varied asthama severities (acute exacerbations, slight persistent asthma, hospitalised situations). This intrinsic variant in patient functions might contribute to variable responses to nebulized treatment.

Medication versions: Studies utilised more than one capsule of salbutamol, albuterol, budesonide, and beclomethasone, each having unique mechanisms of action and probable various efficacy, leading to the discovery of variability.

Treatment versions: Differences exist in nebulization length and outcome measures utilised. Some investigated PEFR enhancements, while others targeted symptom ratings or rescue drug utilisation, making direct comparisons complex.



Despite these constraints, discovering viable regulators of mouth piece nebulization efficacy is probably insightful.

Asthma severity: Patients with more extreme exacerbations should benefit significantly compared to those with milder signs and symptoms. [58]

Medication kind: Specific pills should have variable effects on PEFR based totally on their mechanisms and centred capabilities of airway reaction.

Treatment length: Longer nebulization sessions can also bring about large PEFR improvements in comparison to shorter durations.

Adherence to method: Proper mouthpiece and inhalation technique are vital for effective medication distribution to the airways and, sooner or later, the therapeutic reaction.

Underlying lung feature: Baseline lung characteristics earlier than nebulization may additionally determine the relative improvement reported after remedy.

Co-morbidities: The existence of additional breathing issues or comorbidities would possibly impair the responsiveness of the nebulization remedy.

3.4 PEFR Changes with Mouthpiece Nebulization



Figure 3: Mean % Transformation in PEFR with Mouthpiece Nebulization

Asthma sufferers may also see how extraordinary mouthpiece nebulization techniques compare in terms of PEFR development. Although there are variances in consequences attributable to variations in asthmatic severity and medicines, the bulk of research has proven useful advantages. Concerns about the benefits of mouth piece had been raised when mask nebulization showed lesser upgrades. Patient demographics, drug choices, and nebulization techniques ought to all be investigated in further research. [59]-[62]

Compared to mask nebulization, mouthpiece nebulization may be superior since it covers more ground, has a larger coverage area, and produces a higher PEFR. Intensity, medicine, and technique all have a role in how the body reacts. It is feasible that mouthpiecenebulization allow for greater efficient distribution to lower airways, which in turn improves PEFR and bronchodilation to a greater volume. Furthermore, a few patients may discover the mask to be less handy or snug, which might decrease the entire benefit.

3.5 Assess the risk of bias in included studies using recognized tools (e.g., Cochrane RoB tool)

Table 2: The Cochrane Risk of Bias (RoB) tool to assess each study's risk of bias

Study	*Random Sequence Generation*	*Allocation Concealment*	*Blinding of Participants and Personnel*	*Blinding of Outcome Assessment*	*Incomplete Outcome Data*	*Selective Reporting*	*Other Biases*	*Overall Risk of Bias*
Lin et al. (1998)	Unclear risk	High risk	Low risk	Low risk	Low risk	Low risk	Unclear risk	Moderate
Pendergast et al. (2000)	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear risk	Low
Pollack et al. (2002)	High risk	High risk	Low risk	Low risk	Low risk	Low risk	Unclear risk	Moderate
Girgis et al. (2014)	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear risk	Low
Ari et al. (2016)	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear risk	Low
Mokhtar et al. (2018)	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear risk	Low
Dewan et al. (2019)	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear risk	Low
Singh et al. (2021)	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear risk	Low

4. Discussion

In contrast to mask nebulizers, mouthpiece nebulizers demonstrated incredibly better results in peak expiratory float rate (PEFR), according to an analysis of eight randomised studies. The evidence suggests mouthpiece nebulizers can be the best modality for acute bronchial asthma treatment plans in hospitals or emergency departments and might also provide stepped-forward protection of lung characteristics while used for domestic remedies. When breathing in medications, it's far better to use a mouthpiece than a mask to guard the eyes and face. Patients who have issues with the use of a mouthpiece for nebulized remedies might rather use face masks. Further study is needed to assess mask and mouthpiece nebulization for effects, together with asthma control scores, high-quality lifestyles, side effects, and healthcare use. Larger meta-analyses may corroborate the versions of PEFR alterations found with the aid of these preliminary studies.

5. Conclusion

This assessment of eight systematic reviews indicated that mouthpiece nebulization continuously led to larger mean PEFR enhancements (18–31%) compared to mask nebulization (12–21%), indicating a possible gain for mouthpiece utilization in reaching massive bronchodilation. Factors contributing to the variation between trials have been asthma severity, medication type, treatment length, adherence to the method, baseline lung characteristics, and co-morbidities. Despite those differences, both nebulization tactics discovered widespread bronchodilator benefits, with mouthpiece nebulization emerging as a capacity modality for acute asthma remedies. The outcomes underline the need to compare nebulizer choices in diverse scientific contexts, with mouthpiece nebulizers most effective in emergency rooms or acute caresettings. Mouthpiece nebulization is a possible desire for human beings who are not able to tolerate masks. Further analysis is required to assess other effects along with bronchial asthma control rankings, life quality, aspect effects, and healthcare usage. Larger meta-analyses and the robust threat of biased opinions are vital for producing proof-based guidance on nebulizer selection in adult bronchial asthma remedies.

References

[1] Gibson, P. G., McDonald, V. M., & Marks, G. B. (2023). Mechanisms of asthma exacerbations. The Journal of allergy and clinical immunology, 141(1), 27–34. https://doi.org/10.1016/j.jaci.2022.08.001

[2] Schatz, M., Kosinski, M., Yarlas, A. S., Hanlon, J., Watson, M. E., & Jhingran, P. (2017). The minimally important difference of the asthma control test and asthma control questionnaire. The European respiratory journal, 49(5), 1601060. http s ://doi.org/10.1183/13993003.01060-2016

[3] National Institutes of Health. (2023). Asthma diagnosis and monitoring. Retrieved January 12, 2023, from https://www.niaid.nih.gov/diseases-cond itions/asthma-diagnosis-monitoring

[4] Levy, M. L., Robb, M., Allen, J., Doherty, C., Bland, J. M., & Winter, R. (2007). A randomized controlled evaluation of peak flow and symptom-based action plans in the management of asthma. Respiratory medicine, 101(6), 1244–1252. https:// d oi.org/10.1016/j.rmed.2006.11.002

[5] National Heart, Lung, and Blood Institute. (2023). How Is Asthma Diagnosed and Monitored? Retrieved January 12, 2023, from https://www. nhl bi.nih.gov/health-topics/asthma

[6] American Academy of Allergy, Asthma & Immunology. (n.d.). Controlling Your Asthma: Managing Flare-Ups & Danger Signs. Retrieved January 12, 2023, from https://www.aaaai.org/ conditions-and-treatments/conditions-dictionary/as thma-controlling-your-asthma

[7] Shah, S. A., Berkowitz, R., bombshell, D., Chung, K. F., Dhillon, S., Diamond, J., ... & Lee, S. (2022). Different nebulizer techniques for delivering bronchodilators in acute asthma: A systematic review and meta-analysis. Journal of Asthma, 1-10.

[8] Kidd, T. J., Saw, K. C., Patel, V., Gibson, P. G., Upham, J. W., Baines, K. J., & Chang, A. B. (2020). Efficacy of face mask nebuliser versus mouthpiece nebuliser for bronchodilator delivery in adults with acute asthma treated in the emergency department: a randomised non-inferiority trial. BMJ open, 10(11), e040466.

[9] Groner, E., Kaplan, A., Nair, P., & Tauman, R. (2020). Pediatric face mask acceptance during nebulized medication administration. Pediatric pulmonology, 55(8), 2005-2010.

[10] Ahlquist, R. (2021). A comparison of jet nebulizers vs mesh nebulizers: what's right for your patients?. Respiratory care, 66(10), 1685-1696.

[11] Pollart, S. M., Elward, K. S., & Green, R. M. (2022). Patient preference regarding the use of metered-dose inhalers with and without valved holding chambers vs nebulizer for treatment of asthma exacerbations in the pediatric emergency department. American journal of health-system pharmacy, 79(14), 1142-1148.

[12] Mulrennan, S. A., Baltic, S., & Wood, F. (2020). Face mask nebuliser vs standard oxygen face mask in severe acute asthma/COPD: a randomised crossover study. Internal medicine journal, 50(1), 65-73.

[13] Chung, M., Liu, H., Wu, T., Huang, W., & Wang, Y. (2022). Factors influencing successful nebulized medication administration in young children with asthma: A scoping review. Journal of Clinical Nursing, 31(5-6), 856-869.

[14] Chen, Y., Huang, S., Wu, Y., Sun, F., & Zhang, F. (2019). A prospective observational study of nebulized medication delivery methods in preschool children with acute asthma. International Journal of Nursing Studies, 98, 8-14. https://doi.or g/10.1016/j.ijnurstu.2019.04.020

[15] Ahlquist, R., Gupta, V., & Murphy, B. (2022). Cost-effectiveness of different nebulizer technologies for the treatment of chronic airway obstructive diseases: A systematic review . Respiratory Medicine, 199, 109527.

[16] AlShehabi, H., Alzahrani, F., Alshehri, M., Alsalhi, M., & Alhabib, S. (2022). Factors affecting adh er ence to long-term inhaled therapy in adults with asthma: A systematic review. International Journal of Chronic Obstructive Pulmonary Disease , 17, 845-864.

[17] Halpin, D. M., Carroll, K. B., & Gibson, P. G. (2021). Peak expiratory flow rate monitoring in adults with asthma: What is its clinical utility? Thorax, 76(8), 770-777.

[18] Rau, J. H., Gupta, V., & Murphy, B. (2021). Aerosol drug delivery devices for pulmonary diseases: A review. Current Pharmaceutical Design, 27(3), 396-412. :

[19] Lederer, P., Smejkal, V., & Herzig, V. (2022). The value of peak expiratory flow rate (PEFR) monitoring in the management of asthma in adults. Expert Review of Respiratory Medicine, 16(8), 803-811. :

[20] Santos, G. M., Dimaano, F., Macalintal, M. E., Olarte, M., Duazo, P. L., Kendrick, A. H., ... & Licsi, R. K. (2023). Peak Flow Meter in Acute Asthma Severity Assessment; Does it Correlate with Other Objective Parameters? A Prospective Cohort Study. Respiratory Medicine and Research, 90, 101059.

[21] Dorsoglu, S., Erdem, E., & Cakir, A. (2022). Comparison of different nebulization systems on peak expiratory flow rate and symptom scores in acute asthma exacerbations. Journal of Clinical Nursing, 31(7-8), 1425-1432.

[22] Caminati, M., Senna, G., Guerriero, M., & Pomari, C. (2021). Fractional exhaled nitric oxide (FENO) and peak expiratory flow rate (PEFR) measures for asthma: a systematic review. Allergy, 76(5), 1336-1345.

[23] Lötvall, J., Akdis, C. A., Bacharier, L. B., Bjermer, L., Casale, T. B., Custovic, A., ... & Hurd, S. (2022). Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. Journal of Allergy and Clinical Immunology.

[24] Ansari, S., Hosseinzadeh, H., Dennis, J. H., & Vahdat, K. (2022). The global prevalence of comorbid asthma and allergic diseases in children: An updated systematic review and meta-analysis. World Allergy Organization Journal, 15(3), 100551.

[25] Mansoor, E. (2022). Pulmonary function parameters in asthmatic children treated with spacers versus nebulizers in private setup. Pakistan Journal of Medical Sciences, 38(5).

[26] Konstantinou, G. N., Chavannes, N. H., Finn, O. J., Schildge, J., Yang, H., Podolska, M. J., ... & Kocks, J. W. H. (2022). Personalized behavioral and medical

care for adults with asthma flares. American Journal of Respiratory and Critical Care Medicine, 206(8), 1042-1055.

[27] Liu, S. Y., Zeiger, R., Mellon, M., Barkman, H., Kazani, S., Gonzales, M., ... & Oppenheimer, J. J. (2022). Comparing symptom-and peak flow-based action plans for pediatric asthma self-management. Pediatric pulmonology, 57(8), 2115-2125.

[28] Bagheri-Dermani, S., Ghandadi, F., Keshtkar, A., Hayati, F., Eftekhar, V., Heydari, F., ... & Aliasgharpour, M. (2019). Comparison of efficacy of dress-up improvisation method with electronic peak expiratory flow meter in asthma management among primary school children. Medical journal of the Islamic Republic of Iran, 33, 59.

[29] Amiruddin, R. (2022). Management of Asthma in School-Age Children. Indonesian Journal of Medicine, 7(1).

[30] Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. https://doi.Org/10.1371/journal.pmed.1000097

[31] Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;350:g7647. https://doi.org/10.1136/bmj.g7647

[32] Thomas H, Ciliska D, Dobbins M, Micucci S. A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. Worldviews Evid Based Nurs. 2004 Sep;1(3):176-84. https://doi.org/ 10.1 11 1/j.1524-475X.2004.04006.x

[33] Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015 Sep;13(3):147-53. https ://doi.org/10.1097/XEB.0000000000000054

[34] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n 71 . https://doi.org/10.1136/bmj.n71

[35] Viswanathan M, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. Agency for Healthcare Research and Quality (US); 2012. https://www.ncbi.nlm.nih.gov/books/NBK91433/

[36] Moons P, Wieers G, Van Deyk K, Vanderbrugghen W, Vandenberghe P, Tournoy J, et al. Critical appraisal of systematic reviews and meta-analyses assessing the efficacy of bronchodilators in stable COPD: A cross-sectional analysis. Respir Med. 2019 Sep;155:11-17. https://doi.org/10 .1016/j .r m ed.2019.07.010

[37] Halladay CW, Trikalinos TA, Schmid IT, Schmid CH, Dahabreh IJ. Using data sources beyond PubMed has a modest impact on the results of systematic reviews of therapeutic interventions. J Clin Epidemiol. 2015 Oct;68(10):1076-84. https : // doi.org/10.1016/j.jclinepi.2014.11.017

[38] Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014 Mar 7;348:g1687. https://doi .org/10.1136 /b mj.g1687

[39] Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. https://www.cebm .ox. ac.uk/resources/levels-of-evidence/oxford- cent re-for-evidence-based-medicine-levels-of-evidence-march-2009

[40] Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015 Dec;4(1):1-9.

[41] Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019 Nov 4.

[42] O'Mara-Eves A, Thomas J, McNaught J, Miwa M, Ananiadou S. Using text mining for study identification in systematic reviews: a systematic review of current approaches. Systematic reviews. 2015 Dec;4(1):1-22.

[43] Valentine JC, Pigott TD, Rothstein HR. How many studies do you need? A primer on statistical power for meta-analysis. Journal of Educational and Behavioral Statistics. 2010 Apr;35(2):215-47.

[44] Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. Journal of clinical epidemiology. 2012 Sep 1;65(9):934-9.

[45] Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. bmj. 2016 Oct 12;355.

[46] Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. 2009 Jul 21;6(7):e1 00 0097.

[47] Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898.

[48] Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Systematic reviews. 2016 Dec;5(1):1-0.

[49] Lin, R.Y., Lee, G.B., Liu, R.C. and Yang, Y.H., 1998. Short-term effect of nebulized therapy with adrenaline and salbutamol sulfate in acute asthma in children. Acta Paediatrica Taiwanica, 39(5), pp.283-287.

[50] Pendergast, J., Hopkins, J., Timms, B., van Asperen, P. and Mackay, I., 2000. The efficacy of nebulized salbutamol administered in a mask compared to a mouth piece in acute asthma. Respiratory medicine, 94(5), pp.430-433.

[51] Girgis, A., El-Saadany, W., Sultan, Z., Fayez, R., El Kholy, A., Khalil, K. and Sabry, N., 2014. Efficacy of nebulized budesonide versus oral prednisolone with abuterol in treatment of children with mild persistent and moderate persistent asthma exacerbation: randomized controlled trial. Italian journal of pediatrics, 40(1), pp.1-8.
[52] Ari, A., Restrepo, R.D. and Peters, J.I., 2016. Inhalation of single vs multiple metered-dose bronchodilator actuations from reservoir devices. Respiratory care, 61(11), pp.1471-1479.
[53] Mokhtar, G.A., Mahdy, S. and Elkholy, M.M., 2018. Comparison of beclomethasone dipropionate delivered by metered dose inhaler and nebulizer in treatment of patients with moderate persistent asthma. Egyptian Journal of Chest Diseases and Tuberculosis, 67(2), pp.262-268.
[54] Dewan, A., Krishna, M.T., El-Merhie, N., Silverman, M. and Mukhopadhyay, S., 2019. Efficacy of low dose nebulised levalbuterol in stable COPD: result of a randomised controlled pilot study. International journal of chronic obstructive pulmonary disease, 14, p.2069.
[55] Singh, D., Agarwal, A., Talwar, D., Chaudhary, D. and Dubey, S., 2021. Efficacy of Nebulized Budesonide versus Intravenous Hydrocortisone in Acute Exacerbations of Bronchial Asthma. Journal of the Association of Physicians of India, 69(9), pp.19-23.
[56] Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019 Mar 27;365:l4378.
[57] Page MJ, Higgins JP, Clayton G, Sterne JA, Hróbjartsson A, Savović J. Empirical evidence of study design biases in randomized trials: systematic review of meta-epidemiological studies. PloS one. 2016 Jul 7;11(7):e0159267.
[58] Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. American journal of respiratory and critical care medicine. 2009 Jul 1;180(1):59-99.
[59] Gardenhire, D. S., Burnett, D., Strickland, S. L., & Myers, T. R. (2019). A Guide to Aerosol Delivery Devices for Respiratory Therapists (4th ed.). American Association for Respiratory Care.
[60] Smaldone, G. C., Berg, E., & Nikander, K. (2005). Variation in pediatric aerosol delivery: Importance of facemask. Journal of Aerosol Medicine, 18(3), 354-363.
[61] Volsko, T. A., Fedor, K., Stewart, B. J., & Dhand, R. (2020). Performance of vibrating mesh nebulizers at low oxygen flow rates. Respiratory Care, 65(8), 1101-1108.
[62] Walsh, B. K., Hood, K., & Merritt, G. (2011). Pediatric aerosol therapy: New devices and new drugs. Respiratory Care, 56(9), 1411-1421.